Circio Holding ASA (OSL:CRNA) Research & Development : kr23.94 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Circio Holding ASA's Research & Development for the three months ended in Dec. 2023 was kr0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was kr23.94 Mil.

Circio Holding ASA Research & Development Historical Data

The historical data trend for Circio Holding ASA's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA Research & Development Chart

Circio Holding ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

80.29

45.04

37.44

47.23

49.89

Circio Holding ASA Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Dec23
Research & Development	Get a 7-Day Free Trial															13.94	8.11	15.83	-	-

Circio Holding ASA Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr23.94 Mil.

Circio Holding ASA (OSL:CRNA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Circio Holding ASA Research & Development Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Circio Holding ASA (OSL:CRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

TA50:Germany

Address

Vollsveien 19, Lysaker, Oslo, NOR, 1366

Website

https://www.circio.com

Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines